Literature DB >> 23178825

miR-106a overexpression and pRB downregulation in sporadic colorectal cancer.

T Catela Ivkovic1, G Aralica, T Cacev, B Loncar, S Kapitanovic.   

Abstract

Rb1 plays an important role in cell cycle progression and therefore may be involved in malignant transformation of colonic cells. The aim of our research was to define the potential role of Rb1 as a prognostic biomarker in tumorigenesis of sporadic colorectal cancer, and to examine the role of miR-106a in Rb1 regulation as it functionally binds to 3'UTR of transcribed mRNA. We examined LOH and promoter methylation status. Real-time PCR was used for Rb1 mRNA and miR-106a, and immunohistochemistry for protein expression analysis. All the results obtained from patients' samples were correlated with the clinicopathological parameters in order to determine its influence on the sporadic colorectal carcinogenesis. LOH showed no correlation with mRNA and pRb expression. 51.5% of tumor samples were scored negative for pRb staining. Despite this finding, we detected overexpression of Rb1 mRNA in tumor samples in comparison to the adjacent normal tissue (p=0.023). mRNA overexpression was consistent with Rb1 promoter methylation analysis results, which showed no methylation in the investigated samples. Expression analysis of miR-106a in the patients samples showed its overexpression in colorectal cancer (p<10(-4)). Negative pRb score was expected according to the definition of tumor suppressor genes and their proposed role in the malignant transformation of the cells. The observed discrepancy between mRNA and protein expression can be explained by a regulatory mechanism that inhibits translation, such as microRNA silencing. Our results suggest that miR-106a might have a regulatory role for Rb1 in sporadic colorectal cancer.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178825     DOI: 10.1016/j.yexmp.2012.11.002

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  17 in total

Review 1.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

2.  Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.

Authors:  J B Kjersem; T Ikdahl; O C Lingjaerde; T Guren; K M Tveit; E H Kure
Journal:  Mol Oncol       Date:  2013-09-21       Impact factor: 6.603

3.  miR-106a suppresses tumor cells death in colorectal cancer through targeting ATG7.

Authors:  Haibin Hao; Guangfeng Xia; Chao Wang; Fuping Zhong; Laipeng Liu; Dong Zhang
Journal:  Med Mol Morphol       Date:  2016-12-15       Impact factor: 2.309

4.  MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.

Authors:  Yu-Mei Rao; Hui-Rong Shi; Mei Ji; Cai-Hong Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-08-01

5.  Upregulated expression of miR-106a by DNA hypomethylation plays an oncogenic role in hepatocellular carcinoma.

Authors:  Renshun Yuan; Qiaoming Zhi; Hong Zhao; Ye Han; Ling Gao; Bin Wang; Zhongyang Kou; Zhaoji Guo; Songbing He; Xiaofeng Xue; Hao Hu
Journal:  Tumour Biol       Date:  2014-12-16

6.  miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.

Authors:  Zhaojian Liu; Elizabeth Gersbach; Xiyu Zhang; Xiaofei Xu; Ruifen Dong; Peng Lee; Jinsong Liu; Beihua Kong; Changshun Shao; Jian-Jun Wei
Journal:  Mol Cancer Res       Date:  2013-09-17       Impact factor: 5.852

7.  Dysregulation of miRNAs and their potential as biomarkers for the diagnosis of gastric cancer.

Authors:  Bo Guo; Jie Li; Liying Liu; Ni Hou; Dongmin Chang; Lingyu Zhao; Zongfang Li; Tusheng Song; Chen Huang
Journal:  Biomed Rep       Date:  2013-09-25

Review 8.  Non-coding landscapes of colorectal cancer.

Authors:  Marco Ragusa; Cristina Barbagallo; Luisa Statello; Angelo Giuseppe Condorelli; Rosalia Battaglia; Lucia Tamburello; Davide Barbagallo; Cinzia Di Pietro; Michele Purrello
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

9.  The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines.

Authors:  Qin Wang; Zhenlian Wang; LinYang Chu; Xu Li; Pengcheng Kan; Xin Xin; Yu Zhu; Ping Yang
Journal:  PLoS One       Date:  2015-05-07       Impact factor: 3.240

10.  Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma.

Authors:  Qingbao Cheng; Feiling Feng; Lumin Zhu; Yanhua Zheng; Xiangji Luo; Chen Liu; Bin Yi; Xiaoqing Jiang
Journal:  Sci Rep       Date:  2015-11-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.